AMLX vs J · rev $87.4M vs P/E 36, $14.40B cap
Amylyx Pharmaceuticals Inc (AMLX) versus Jacobs Solutions Inc. (J) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
Jacobs Solutions Inc. (J) is a engineering & construction company listed on US.
Latest reported AMLX revenue for 2024-12-31 was $87.4M. Net income was -$301.7M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AMLX currently screens at market cap $561.6M.
J does not have a complete income-statement cache yet.
AMLX currently screens at market cap $561.6M. J currently screens at market cap $14.40B and trailing P/E 36.0.
Not investment advice. Open the AMLX and J stock pages for the full models.
Not investment advice.